Barclays lowered the firm’s price target on Syndax (SNDX) to $19 from $33 and keeps an Overweight rating on the shares as part of a Q1 earnings ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Max, formerly known as HBO Max, officially has a new logo on Sunday night, March 30. The new logo for Warner Bros. Discovery's steaming platform was unveiled on Sunday evening. The new logo gives ...

Syndax Pharmaceuticals , a clinical-stage biopharmaceutical company focusing on cancer treatments, exemplified the challenges of accurately valuing high-growth biotech companies. When our Fair Value ...

Also Read: FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication JPMorgan says that, on average, surveyed physicians treated 8 KMT2A acute ...

Syndax Pharmaceuticals traded as high as $13.51 and last traded at $13.84. 164,424 shares were traded during mid-day trading, a decline of 89% from the average session volume of 1,439,839 shares ...

Write to [email protected] Syndax Pharmaceuticals NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

On Tuesday, H.C. Wainwright affirmed its Buy rating on shares of Syndax Pharmaceuticals (NASDAQ:SNDX), maintaining a $51.00... On Tuesday, BTIG analyst Justin Zelin confirmed a Buy rating on ...

The Revitalising the PNG Dictionary of Biography (PNGDB) Project is an attempt to celebrate Papua New Guineans from various sectors of society who have contributed to progressing the nation’s ...